Leyden Labs secures $70M to advance intranasal antibody therapies
Summary
A new \xa312.5m Series B expansion brings Elipsogen Ltds total Series B funds raised to \xa343.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept more
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected